Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:32:48 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:MRNA - MODERNA INC - https://www.modernatx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRNA - Q8.848.56·48.900.349.04-0.99-2.07,232.5346,96954,46848.43  49.88  47.9159.5494  22.2919:58:30May 1215 min RT 2¢

Recent Trades - Last 10 of 54468
Time ETExPriceChangeVolume
19:58:30Q48.98-1.051
19:53:37Q48.7731-1.256926
19:53:26Q48.99-1.043
19:51:41Q49.00-1.031
19:47:31Q48.80-1.231
19:45:18Q48.5715-1.4585100
19:43:21Q48.5525-1.4775293
19:42:51Q48.50-1.532
19:42:21Q48.87-1.1640
19:33:53Q48.87-1.1610

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-12 17:05U:MRNANews ReleaseModerna Recognized by TIME as One of the World's Most Impactful Companies
2026-05-11 08:30U:MRNANews ReleaseCNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
2026-05-06 17:16U:MRNANews ReleaseModerna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
2026-05-01 06:30U:MRNANews ReleaseModerna Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-21 19:01U:MRNANews ReleaseModerna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
2026-04-21 10:00U:MRNANews ReleaseModerna Announces Data to be Presented at 2026 ASCO Annual Meeting
2026-04-21 09:41U:MRNANews ReleaseModerna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
2026-04-21 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conferences in May 2026
2026-04-17 15:00U:MRNANews ReleaseModerna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting
2026-04-15 07:00U:MRNANews ReleaseModerna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
2026-04-06 18:01U:MRNANews ReleaseModerna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
2026-03-03 16:15U:MRNANews ReleaseModerna Resolves Global Patent Litigation with Arbutus/Genevant
2026-02-27 07:00U:MRNANews ReleaseEuropean Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
2026-02-23 16:01U:MRNANews ReleaseTectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board
2026-02-19 07:00U:MRNANews ReleaseModerna to Present at Upcoming Conferences in March 2026
2026-02-18 07:00U:MRNANews ReleaseModerna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
2026-02-17 07:00U:MRNANews ReleaseModerna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
2026-02-13 07:00U:MRNANews ReleaseModerna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
2026-02-10 18:00U:MRNANews ReleaseModerna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010